

REFERENSI

- Abdullah, K., Jannah, M., Aiman, U., Hasda, S., Fadilla, Z., Taqwin, Masita, Ardiawan, K. N., & Sari., M. E. (2021). *Metodologi Penelitian Kuantitatif* (N. Saputra (ed.)). Yayasan Penerbit Muhammad Zaini.
- Abrahams, H. J. G., Gielissen, M. F. M., Schmits, I. C., Verhagen, C. A. H. H. V. M., Rovers, M. M., & Knoop, H. (2016). Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: A meta-analysis involving 12 327 breast cancer survivors. *Annals of Oncology*, 27(6), 965–974. <https://doi.org/10.1093/annonc/mdw099>
- Akbari, M. esmaeil, Ghelichi-Ghojogh, M., Nikeghbalian, Z., Karami, M., Akbari, A., Hashemi, M., Nooraei, S., Ghiasi, M., Fararouei, M., & Moradian, F. (2022). Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study. *Annals of Medicine and Surgery*, 84(104921), 1–8. <https://doi.org/10.1016/j.amsu.2022.104921>
- Alkabban, F. M., & Ferguson, T. (2022). Breast Cancer. Treasure Island (FL): StatPearls Publishing. Dipetik January 12, 2023, dari <https://www.ncbi.nlm.nih.gov/books/NBK482286/>
- American Cancer Society. (2019, November 22). *How Is Chemotherapy Used to Treat Cancer?* Dipetik January 13, 2023, dari American Cancer Society: <https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy/how-is-chemotherapy-used-to-treat-cancer.html>
- Amjad, M. T., Chidharla, A., & Kasi, A. (2023). Cancer Chemotherapy. Treasure Island (FL): StatPearls Publishing. Dipetik January 13, 2023, dari <https://www.ncbi.nlm.nih.gov/books/NBK564367/>
- Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez de la Lastra, J. M. (2023). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes and Diseases*, 10(4), 1367–1401. <https://doi.org/10.1016/j.gendis.2022.02.007>
- Andersen, M. K., Christiansen, D. H., Jensen, B. A., Ernst, P., Hauge, G., & Pedersen-Bjergaard, J. (2001). Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. *British Journal of Haematology*, 114(3), 539–543. <https://doi.org/10.1046/j.1365-2141.2001.03000.x>
- Anjum, F., Razvi, N., & Saeed, U. (2017). Effects of Chemotherapy in Breast Cancer Patients. *National Journal of Health Sciences*, 2(2), 67–74.

<https://doi.org/10.21089/njhs.22.0067>

- Aogi, K., Watanabe, K., Kitada, M., Sangai, T., Ohtani, S., Aruga, T., Kawagichi, H., Fujisawa, T., Maeda, S., Morimoto, T., Sato, N., Takao, S., Morita, S., Masuda, N., Toi, M., & Ohno, S. (2021). Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). *International Journal of Clinical Oncology*, 26(7), 1229–1236. <https://doi.org/10.1007/s10147-021-01920-0>
- Apriyanti, N. K. V., Dewi, N. N. A., & Surudarma, I. W. (2020). Karakteristik sosiodemografi, paparan hormon, dan tumor pada pasien kanker payudara di RSUP Sanglah, Denpasar (Kasus September-November 2016). *Jurnal Medika Udayana*, 9(6), 63–69. <https://doi.org/https://ojs.unud.ac.id/index.php/eum> doi:10.24843.MU.2020.V9.i6.P13
- Ashariati, A., Sedana, M. P., Bintoro, U. Y., Diansyah, M. N., Amrita, P. N. A., Savitri, M., Romadhon, P. Z., & Permatasari, A. (2019). *Manajemen Kanker Payudara Komprehensif* (1st ed.). Universitas Airlangga Press. [https://repository.unair.ac.id/96210/2/Manajemen Kanker Payudara Komprehensif.pdf](https://repository.unair.ac.id/96210/2/Manajemen_Kanker_Payudara_Komprehensif.pdf)
- Atalay, C., & Küçük, A. I. (2015). The impact of weight gain during adjuvant chemotherapy on survival in breast cancer. *Turkish Journal of Surgery*, 31(3), 124–127. <https://doi.org/10.5152/UCD.2015.3123>
- Ayash, L., Korb, T., Herman, T. S., & Teicher, B. A. (1991). Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells. *Cancer Letters*, 61(1), 7–14. [https://doi.org/10.1016/0304-3835\(91\)90070-X](https://doi.org/10.1016/0304-3835(91)90070-X)
- Azubuike, S. O., Hayes, L., Sharp, L., Alabi, A., Oyesegun, R., & McNally, R. (2022). Socio-economic status and the risk of breast cancer among Nigerian women: a case control study. *Pan African Medical Journal*, 41(175), 1–19. <https://doi.org/10.11604/pamj.2022.41.175.32914>
- Berg, M. M. G. A., Winkels, R. M., Kruif, J. T. C. M., Laarhoven, H. W. M., Visser, M., Vries, J. H. M., Vries, Y. C., & Kampman, E. (2017). Weight change during chemotherapy in breast cancer patients: A meta-analysis. *BMC Cancer*, 17(1), 1–13. <https://doi.org/10.1186/s12885-017-3242-4>
- Berger, E., Maitre, N., Romana Mancini, F., Baglietto, L., Perduca, V., Colineaux, H., Sieri, S., Panico, S., Sacerdote, C., Tumino, R., Vineis, P., Boutron-Ruault, M. C., Severi, G., Castagné, R., & Delpierre, C. (2020). The impact of lifecourse socio-economic position and individual social mobility on breast cancer risk. *BMC Cancer*, 20(1), 1–11. <https://doi.org/10.1186/s12885-020-07648-w>
- Budiani, K., Abdurahman, M., & Rizki, K. A. (2020). Hubungan Antara Perubahan Indeks Massa Tubuh (IMT) dengan Respon Kemoterapi Neoadjuvan Kombinasi Doksorubisin pada Penderita Kanker Payudara Lanjut Lokal di

- RSUP Dr. Hasan Sadikin Bandung. *Jurnal Ilmu Bedah Indonesia*, 48(2), 3–21. <https://doi.org/10.46800/jibi-ikabi.v48i2.61>
- Burguin, A., Diorio, C., & Durocher, F. (2021). Breast cancer treatments: Updates and new challenges. *Journal of Personalized Medicine*, 11(808), 1–54. <https://doi.org/10.3390/jpm11080808>
- Cancer Research UK. (2022). *Eribulin (Halaven)*. Cancer Research UK. <https://www.cancerresearchuk.org/about-cancer/treatment/drugs/eribulin>
- Chaveepojnkamjorn, W., Pichainarong, N., Thotong, R., Sativipawee, P., & Pitikultang, S. (2017). Relationship between breast cancer and oral contraceptive use among Thai premenopausal women: A case-control study. *Asian Pacific Journal of Cancer Prevention*, 18(5), 1429–1433. <https://doi.org/10.22034/APJCP.2017.18.5.1429>
- Christos, K. K., Maria-Ioanna, C., & Andreas, S. (2014). Apoptosis-related BCL2-family Members: Key Players in Chemotherapy. In *Anti-Cancer Agents in Medicinal Chemistry* (Vol. 14, Issue 3, pp. 353–374). <https://doi.org/http://dx.doi.org/10.2174/18715206113139990091>
- Ciria-Suarez, L., Jiménez-Fonseca, P., Palacín-Lois, M., Antoñanzas-Basa, M., Fernández-Montes, A., Manzano-Fernández, A., Castelo, B., Asensio-Martínez, E., Hernando-Polo, S., & Calderon, C. (2021). Breast cancer patient experiences through a journey map: A qualitative study. *PLoS ONE*, 16(9), 1–23. <https://doi.org/10.1371/journal.pone.0257680>
- Darmawan, E., Melani, R., & Raharjo, B. (2019). Gambaran Hubungan Regimen Dosis Danefek Samping Kemoterapi pada Pasien Kanker di RSUD Prof Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019. *Majalah Farmaseutik*, 15(2), 113–122. <https://doi.org/10.22146/farmaseutik.v15i2.47664>
- DePolo, J. (2023, October 13). *Breast Cancer Stages*. (B. Wojciechowski, Editor) Dipetik January 12, 2024, dari Breastcancer.org: <https://www.breastcancer.org/pathology-report/breast-cancer-stages>
- Ding, W., Li, Z., Wang, C., Dai, J., Ruan, G. D., & Tu, C. (2018). Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer A systematic review and meta-analysis. *Medicine (United States)*, 97(42), 1–7. <https://doi.org/10.1097/MD.00000000000012908>
- Febriani, A., & Rahmawati, Y. (2019). Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. *Jurnal Respirasi*, 5(1), 22–28. <https://doi.org/10.20473/jr.v5-i.1.2019.22-28>
- Febrianti, R., & Wahidin, M. (2021). Hubungan Usia dan Riwayat Keluarga dengan Kejadian Kanker Payudara di Rsup Dr M. Djamil Padang Tahun 2021. *Journal of Scientech Research and Development*, 3(1), 16–23. <https://idm.or.id/JSCR/index.php/JSCR/article/view/14>

- Greif, J. M., Pezzi, C. M., Klimberg, S. V., Bailey, L., & Zuraek, M. (2012). Gender differences in breast cancer: Analysis of 13,000 breast cancers in men from the national cancer data base. *Annals of Surgical Oncology*, 19(10), 3199–3204. <https://doi.org/10.1245/s10434-012-2479-z>
- Habsari, A., Pradigdo, S. F., & Aruben, R. (2017). Hubungan Beberapa Faktor Gizi Dan Kemoterapi Dengan Status Gizi Penderita Kanker (Studi Kasus Di Instalasi Rawat Jalan Poli Onkologi Rsud Dr. Soehadi Prijonegoro Kabupaten Sragen Tahun 2017). *Jurnal Kesehatan Masyarakat (e-Journal)*, 5(4), 593–599. <https://doi.org/https://doi.org/10.14710/jkm.v5i4.18723>
- Harlin, S. T. (2019). Hubungan Pendidikan dan Pengetahuan Wanita Dewasa terhadap Perilaku Pencegahan Kanker Payudara dan Kanker Serviks di Lingkungan Keluarga Binaan Kesehatan Kelurahan Tegal Sari Mandala II. *Skripsi*, 1(1), 1–102. http://www.ghbook.ir/index.php?name=فرهنگ و رسانه های نوین&option=com_dbook&task=readonline&book_id=13650&page=73&chhashk=ED9C9491B4&Itemid=218&lang=fa&tmpl=component%0Ahttp://www.albayan.ae%0Ahttps://scholar.google.co.id/scholar?hl=en&q=APLIKASI+PENGENA
- Henry, D. H., Viswanathan, H. N., Elkin, E. P., Traina, S., Wade, S., & Cella, D. (2008). Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. *Supportive Care in Cancer*, 16(7), 791–801. <https://doi.org/10.1007/s00520-007-0380-2>
- Hoseini, Z. S., Ghouchani, H. T., Hakak, H. M., Lashkardoost, H., Mehri, A., Khankolabi, M., & Salari, E. (2021). Effect of Education on Promoting Healthy Lifestyle Behaviors That Prevent Breast Cancer in Middle-Aged Women: Application of Protection Motivation Theory. *Korean Journal of Family Medicine*, 42(2), 166–171. <https://doi.org/10.4082/kjfm.19.0164>
- Ingrand, I., Defosse, G., Lafay-Chebassier, C., Chavant, F., Ferru, A., Ingrand, P., & Pérault-Pochat, M. C. (2020). Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey. *British Journal of Clinical Pharmacology*, 86(4), 711–722. <https://doi.org/10.1111/bcp.14159>
- Jang, M. K., Park, S., Park, C., Doorenbos, A., Go, J., & Kim, S. (2023). Hematologic toxicities, sarcopenia, and body composition change in breast cancer patients undergoing neoadjuvant chemotherapy. *Supportive Care in Cancer*, 31(7), 419. <https://doi.org/10.1007/s00520-023-07890-5>
- Katta, B., Vijayakumar, C., Dutta, S., Dubashi, B., & Nelamangala Ramakrishnaiah, V. P. (2023). The Incidence and Severity of Patient-Reported Side Effects of Chemotherapy in Routine Clinical Care: A Prospective Observational Study. *Cureus*, 15(4), 1–7. <https://doi.org/10.7759/cureus.38301>
- Kemenkes RI. (2017). Petunjuk Teknis: Paliatif Kanker Pada Dewasa. In *Kemenkes RI. DIT.P2PTM*.

http://p2ptm.kemkes.go.id/uploads/VHcrbkVobjRzUDN3UCs4eUJ0dVBndz09/2017/08/PETUNJUK_TEKNIS_PALIATIF_KANKER_PADA_DEWAS A.pdf

- Kemenkes RI. (2019). Laporan Riskesdas 2018 Kementrian Kesehatan Republik Indonesia. In *Badan Penelitian dan Pengembangan Kesehatan* (Vol. 53, Issue 9). [http://www.yankes.kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf](http://www.yankes.kemkes.go.id/assets/downloads/PMK_No_57_Tahun_2013_tentang_PTRM.pdf)
- Kemenkes RI. (2023, February 08). *Satuan Kata dan Langkah*. Dipetik 11 07, 2023, dari Kementerian Kesehatan Reublik Indonesia: https://yankes.kemkes.go.id/view_artikel/2118/
- Kristensen, A., Solheim, T. S., Amundsen, T., Hjelde, H. H., Kaasa, S., Sørhaug, S., & Grønberg, B. H. (2017). Measurement of health-related quality of life during chemotherapy—the importance of timing. *Acta Oncologica*, 56(5), 737–745. <https://doi.org/10.1080/0284186X.2017.1279748>
- Kristensen, A., Solheim, T. S., Fløtten, Ø., & Grønberg, B. H. (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. *Acta Oncologica*, 57(11), 1574–1579. <https://doi.org/10.1080/0284186X.2018.1492151>
- Larsen, A. K., Escargueil, A. E., & Skladanowski, A. (2003). Catalytic topoisomerase II inhibitors in cancer therapy. *Pharmacology and Therapeutics*, 99(2), 167–181. [https://doi.org/10.1016/S0163-7258\(03\)00058-5](https://doi.org/10.1016/S0163-7258(03)00058-5)
- Lee, L., Cheung, W. Y., Atkinson, E., & Krzyzanowska, M. K. (2011). Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. *Journal of Clinical Oncology*, 29(1), 106–117. <https://doi.org/10.1200/JCO.2010.31.3049>
- Lewis, S. L., Dirksen, S. R., Heitkemper, M. M., & Bucher, L. (2014). *Medical-Surgical Nursing: Assessment and Management of Clinical Problems* (M. M. Harding (ed.); 9th ed.). Elsevier, Book Aid International.
- Lukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanislawek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies— An Updated Review. *Cancers*, 13(4287), 1–30. <https://doi.org/https://doi.org/10.3390/cancers13174287>
- Melati, R. S. (2022). *Pengaruh Pendidikan Kesehatan Pemeriksaan Payudara Sendiri (SADARI) Dengan Media Flipchart Terhadap Pengetahuan Deteksi Dini Kanker Payudara Remaja Putri Kelas XII Di SMAN 2 Pangkalan Bun [Sekolah Tinggi Ilmu Kesehatan Borneo Cendekia Media]*. <https://dataindonesia.id/sektor-riil/detail/angka-konsumsi-ikan-ri-naik-jadi-5648-kgkapita-pada-2022>

- Mirsyad, A., Gani, B. G., Karim, M., Purnamasari, R., Karsa, N. S., Tanra, A. H., & Julia, J. (2022). Hubungan Usia Pasien Dengan Tingkat Stadium Kanker Payudara Di RS Ibnu Sina Makassar 2018. *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*, 2(2), 109–115. <https://doi.org/10.33096/fmj.v2i2.48>
- Miyazaki, M., & Yamada, K. (2022). [Promotion of multidisciplinary collaboration in cancer chemotherapy- basic knowledge of medicines for clinical nurses] *Nihon yakurigaku zasshi. Folia Pharmacologica Japonica*, 157(6), 416–420. <https://doi.org/https://doi.org/10.1254/fpj.22048>
- Muthanna, F. M. S., Iqbal, M. S., Karuppannan, M., Abdulrahman, E., Adulyarat, N., Al-Ghorafi, M. A. H. A. A., & Barhoum, H. S. (2022). Prevalence and associated factors of fatigue among breast cancer patients in Malaysia—A prospective study. *Journal of Applied Pharmaceutical Science*, 12(10), 131–139. <https://doi.org/https://doi.org/10.1155/2022/7611733>
- Mutschler, N. S., Scholz, C., Friedl, T. W. P., Zwingers, T., Fasching, P. A., Beckmann, M. W., Fehm, T., Mohrmann, S., Salmen, J., Ziegler, C., Jäger, B., Widschwendter, P., de Gregorio, N., Schochter, F., Mahner, S., Harbeck, N., Weissenbacher, T., Jückstock, J., Janni, W., & Rack, B. (2018). Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. *Clinical Breast Cancer*, 18(2), 175–183. <https://doi.org/10.1016/j.clbc.2018.01.008>
- Nguyen, B., Venet, D., Lambertini, M., Desmedt, C., Salgado, R., Horlings, H. M., Rothé, F., & Sotiriou, C. (2019). Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. *Breast Cancer Research*, 21(1), 1–10. <https://doi.org/10.1186/s13058-019-1111-6>
- Nguyen, S. M., Pham, A. T., Nguyen, L. M., Cai, H., Tran, T. V., Shu, X. O., & Tran, H. T. T. (2022). Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam. *Current Oncology*, 29(11), 8269–8284. <https://doi.org/10.3390/curroncol29110653>
- NIH. (2022, August 23). *Chemotherapy to Treat Cancer*. Dipetik January 13, 2023, dari National Cancer Institute: <https://www.cancer.gov/about-cancer/treatment/types/chemotherapy>
- Ningrum, D. A. R. (2015). Pengaruh Kemoterapi Terhadap Asupan Makan dan Status Gizi Penderita Kanker Nasofaring di Ruang Rawat Inap RSUD Dr. Moewardi Surakarta. In *Universitas Muhammadiyah Surakarta*. Universitas Muhammadiyah Surakarta.
- Pearce, A., Haas, M., Viney, R., Haywood, P., Pearson, S. A., Van Gool, K., Srasuebku, P., & Ward, R. (2015). Can administrative data be used to measure chemotherapy side effects? *Expert Review of Pharmacoeconomics and Outcomes Research*, 15(2), 215–222. <https://doi.org/10.1586/14737167.2015.990888>

- Pranjić, N., Gledo, I., & Maleš-Bilić, L. (2014). The Most Common New Cases of Breast Cancer among the Housewives: The Some Carcinogenic Determinants. *Macedonian Journal of Medical Sciences*, 7, 346–351. <https://doi.org/https://doi.org/10.3889/mjms.1857-5773.2014.0394>
- Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., & Ruiz-Frutos, C. (2020a). Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. *Medicine (United States)*, 99(33), 1–10. <https://doi.org/10.1097/MD.00000000000021695>
- Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., & Ruiz-Frutos, C. (2020b). Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. *Medicine (United States)*, 99(33), E21695. <https://doi.org/10.1097/MD.00000000000021695>
- Pudrovska, T., & Anikputa, B. (2012). The Role of Early-Life Socioeconomic Status in Breast Cancer Incidence and Mortality: Unraveling Life Course Mechanisms. *J Aging Health*, 24(2), 323–344. <https://doi.org/10.1177/0898264311422744>
- Rakshith, H. T., Lohita, S., Rebello, A. P., Goudanavar, P. S., & Raghavendra Naveen, N. (2023). Sex differences in drug effects and/or toxicity in oncology. *Current Research in Pharmacology and Drug Discovery*, 4(June 2022), 100152. <https://doi.org/10.1016/j.crphar.2022.100152>
- Ralhan, R., & Kaur, J. (2007). Alkylating agents and cancer therapy. *Expert Opinion on Therapeutic Patents*, 17(9), 1061–1075. <https://doi.org/10.1517/13543776.17.9.1061>
- Rhonda, K., & Lamos, M. de. (2023). *Cancer Drug Pharmacology Table*. http://www.bccancer.bc.ca/pharmacy-site/Documents/Pharmacology_Table.pdf
- RSWS. (2020). *Laporan Tahunan Periode Tahun 2020*. [https://rsupwahidin.com/plugins/kcfinder/upload/files/LAPTAH RSWS TAHUN 2020.pdf](https://rsupwahidin.com/plugins/kcfinder/upload/files/LAPTAH_RSWS_TAHUN_2020.pdf)
- Saruhan, Ç. (2020). Cancer, Side Effects of Chemotherapy and Nursing Care. *International Journal of Health Services Research and Policy*, 5(1), 51–63. <https://doi.org/10.33457/ijhsrp.670942>
- So, W. K. W., Law, B. M. H., Ng, M. S. N., He, X., Chan, D. N. S., Chan, C. W. H., & McCarthy, A. L. (2021). Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review. *Cancer Medicine*, 10(8), 2531–2565. <https://doi.org/10.1002/cam4.3794>
- Sørensen, B. S., Sinding, J., Andersen, A. H., Alsner, J., Jensen, P. B., & Westergaard, O. (1992). Mode of action of topoisomerase II-targeting agents

- at a specific DNA sequence. *Journal of Molecular Biology*, 228(3), 778–786. [https://doi.org/10.1016/0022-2836\(92\)90863-f](https://doi.org/10.1016/0022-2836(92)90863-f)
- Sulviana, E. R., & Kurniasari, L. (2021). Hubungan Antara Usia, Pendidikan, dan Pekerjaan dengan Kejadian Kanker Payudara pada Wanita di Kalimantan Timur. *Borneo Student Research*, 2(3), 1937–1943. <https://journals.umkt.ac.id/index.php/bsr/article/download/1988/951>
- Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., & Zhu, H. P. (2017). Risk factors and preventions of breast cancer. *International Journal of Biological Sciences*, 13(11), 1387–1397. <https://doi.org/10.7150/ijbs.21635>
- Unger, J. M., Vaidya, R., Albain, K. S., Leblanc, M., Minasian, L. M., Gotay, C. C., Henry, N. L., Fisch, M. J., Lee, S. M., Blanke, C. D., & Hershman, D. L. (2022). Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. *Journal of Clinical Oncology*, 40(13), 1474–1486. <https://doi.org/10.1200/JCO.21.02377>
- Vera, R., Juan-Vidal, O., Safont-Aguilera, M. J., de la Peña, F. A., & del Alba, A. G. (2023). Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach. *Clinical and Translational Oncology*, 25(7), 2069–2076. <https://doi.org/10.1007/s12094-023-03112-w>
- WHO. (2020). *Cancer Indonesia 2020 country profile*. <https://www.who.int/publications/m/item/cancer-idn-2020>
- WHO. (2023, July 12). *Breast Cancer*. Dipetik 11 07, 2023, dari World Health Organization: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- Wijayanti, N., Dr. Fita Rahmawati Sp.FRS., A., & Pramugyono, P. (2023). Kajian Efek Samping Obat Kemoterapi Dosetaksel Pada Kanker Payudara Di RS Bhayangkara Kediri. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, 13(3). <https://doi.org/10.22146/jmpf.83782>
- Yu, L., Han, S., Lang, L., Song, H., Zhang, C. Y., Dong, L., Jia, S. H., Zhang, Y., Xiao, D., Liu, J., Xu, Y., & Zhang, X. P. (2021). Oxocrebaine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest. *Phytomedicine*, 84, 153504. <https://doi.org/10.1016/j.phymed.2021.153504>
- Zhang, H., Barner, J. C., Moczygemba, L. R., Rascati, K. L., Park, C., & Kodali, D. (2023). Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis. *Breast Cancer (Tokyo, Japan)*, 30(3), 489–496. <https://doi.org/10.1007/s12282-023-01441-w>

Zhao, Y., Chen, L., Zheng, X., & Shi, Y. (2022). Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review. *BMJ Open*, 12(11), 1–9. <https://doi.org/10.1136/bmjopen-2022-061967>

LAMPIRAN

Lampiran 1. Lembar Penjelasan Penelitian

LEMBAR PENJELASAN PENELITIAN

Assalamu 'alaikum Warahmatullahi Wabarakatuh,

Sebelumnya, izinkan saya meminta maaf apabila saya telah menyita waktu Saudara(i), perkenalkan, saya Lilian Arifka Juli Abdullah, mahasiswi Program Studi Ilmu Keperawatan Universitas Hasanuddin. Saat ini, saya tengah menjalankan penelitian yang berjudul “Hubungan Pemberian Obat Kemoterapi Terhadap Kejadian Efek Samping Pada Pasien Kanker Payudara Yang Menjalani Kemoterapi Di RSUP Dr. Wahidin Sudirohusodo”.

Untuk itu, saya ingin meminta kesediaan Saudara(i) untuk menjadi responden dalam penelitian tersebut. Dalam pengisian kuesioner ini, tidak ada jawaban yang dianggap benar atau salah. Saya mengharapkan bahwa Saudara(i) dapat mengisi setiap pertanyaan sejujur-jujurnya sesuai dengan apa yang Saudara(i) pilih.

Identitas dan semua informasi Saudara(i) sebagai responden akan dijaga kerahasiaannya oleh peneliti dan akan digunakan hanya untuk keperluan penelitian ini. Peneliti menjamin bahwa penelitian ini tidak merugikan responden dan mengerti jika Saudara(i) tidak bersedia menjadi responden dalam penelitian ini. Demikian penjelasan dari saya, apabila ada hal yang kurang jelas dapat menghubungi saya selaku peneliti (**Kontak/WhatsApp: 085298468656**).

Makassar, / 2024

Peneliti,

(Lilian Arifka Juli)

Lampiran 2. Lembar Persetujuan Responden

LEMBAR PERSETUJUAN RESPONDEN

Saya yang bertandatangan di bawah ini:

Nama :

Jenis Kelamin :

Usia :

Alamat :

Nomor HP :

Setelah membaca dan mengerti penjelasan penelitian yang diberikan oleh peneliti, maka saya menyatakan bersedia menjadi responden dalam penelitian ini dan akan menjawab pertanyaan penelitian sesuai dengan yang saya rasakan/alami. Demikian persetujuan ini saya buat sebenar-benarnya dan tanpa paksaan dari pihak manapun.

Makassar, / 2024

Responden Penelitian

()

Penanggungjawab Penelitian:

Nama : Lilian Arifka Juli Abdullah

Alamat : Jl. Bung Komp. Bumi Bung Permai Blok A11/No.8

Nomor HP : 085298468656

Email : lilyyarifka@gmail.com

Lampiran 3. Lembar Instrumen Penelitian

INSTRUMEN PENELITIAN

“HUBUNGAN PEMBERIAN OBAT KEMOTERAPI DENGAN KEJADIAN EFEK SAMPING PADA PASIEN KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RSUP DR. WAHIDIN SUDIROHUSODO”

Kuesioner ini menanyakan tentang kesehatan Anda pada minggu-minggu setelah pengobatan kemoterapi, dan karena kuesioner ini berusaha mencakup semua kemungkinan, kuesioner ini berisi daftar panjang efek samping yang banyak di antaranya mungkin tidak relevan dengan kasus Anda. Namun, untuk tujuan analisis, mohon berikan jawaban untuk setiap pertanyaan. Sebagian besar jawaban hanya membutuhkan tanda (/), dan kuesioner ini hanya membutuhkan waktu beberapa menit untuk diselesaikan.

Sebagian besar pertanyaan hanya menanyakan apakah Anda mengalami masalah tertentu dalam 3 minggu setelah perawatan terakhir Anda. Kami ingin Anda menilai **tingkat keparahan** masalah pada skala 0–4:

0= Tidak mengalami efek samping sama sekali

1= Ringan

2= Sedang

3= Buruk

4= Sangat buruk

Jawablah dengan memberi tanda silang pada nomor yang sesuai, seperti pada contoh di bawah ini.

① ① ② ~~③~~ ④

Untuk pertanyaan **Ya/Tidak**, mohon **lingkari** jawaban yang sesuai.

Jawablah dengan memberi tanda ✓ pada pertanyaan dengan isian □

Pada pertanyaan dengan tanda (*) maka akan didampingi oleh peneliti saat pengisian dan disesuaikan berdasarkan RM pasien

Keterangan: silahkan gunakan ruang yang tersedia untuk menuliskan keterangan

Tanggal:

Nama:

Jenis Kelamin:

☐ Laki-laki

☐ Perempuan

Tempat dan Tanggal Lahir:

Pekerjaan:

☐ PNS

☐ IRT

☐ Wiraswasta

☐ Pensiunan

☐ Lainnya: _____

Pendidikan Terakhir:

☐ SD sederajat

☐ SMP sederajat

☐ SMA sederajat

☐ DI/DIII/DIV

☐ S1/S2/S3

1. Berat Badan (kg) _____

2. Stadium Klinis Kanker saat ini*:

☐ Stadium 0

☐ IA

☐ IB

☐ IIA

☐ IIB

☐ IIIA

☐ IIIB

☐ IIIC

☐ IV

3. Siklus Kemoterapi saat ini*:

☐ Siklus 1

☐ 2

☐ 3

☐ 4

☐ 5

☐ 6

☐ 7

☐ 8

4. Jenis obat kemoterapi yang digunakan*:

5. Riwayat Penyakit Lainnya: _____

Dalam 3 minggu setelah pengobatan kemoterapi terakhir Anda, apakah Anda mengalami salah satu dari masalah berikut ini? Mohon sebutkan tingkat keparahan masalah pada skala 0–4.

A: Sistem Pencernaan

6. **Mual** ① ② ③ ④
7. Jika Anda mengalami mual, berapa lama hal ini berlangsung? (hari)
.....
8. **Muntah** ya/tidak
9. Jika Anda mengalami muntah, berapa kali hal ini terjadi?.....
10. Lebih dari berapa jam/hari ini?.....
11. **Sembelit (Susah BAB)** ① ② ③ ④
12. **Diare** ① ② ③ ④
13. **BAB lebih sering** ① ② ③ ④
14. **BAK lebih sering** ① ② ③ ④
15. **Lainnya (sebutkan spesifik)** ① ② ③ ④

B: Mulut dan Hidung

16. **Mulut sakit/sensitive** ① ② ③ ④
17. **Gusi sakit/sensitif** ① ② ③ ④
18. **Bibir terasa perih/sensitif** ① ② ③ ④
19. **Lidah sakit/sensitif** ① ② ③ ④
20. **Mulut kering** ① ② ③ ④
21. **Bibir kering** ① ② ③ ④
22. **Sariawan (mulut atau lidah)** ① ② ③ ④
23. **Kehilangan rasa atau perubahan rasa** ① ② ③ ④
24. **Kehilangan indera penciuman** ① ② ③ ④
25. **Indera penciuman yang meningkat** ① ② ③ ④
26. **Masalah hidung (sebutkan spesifik)** ① ② ③ ④
27. **Lainnya (sebutkan spesifik)** ① ② ③ ④

C: Rambut dan Kulit

28. **Kuku rapuh** ① ② ③ ④
29. **Kuku bergelombang atau bertekstur** ① ② ③ ④
30. **Kulit sensitive atau “tipis”** ① ② ③ ④
31. **Kulit kurang sensitif atau “mati rasa”** ① ② ③ ④
32. **Kulit gatal** ① ② ③ ④
33. **Peradangan kulit** ① ② ③ ④
34. **Kesemutan** ① ② ③ ④
35. **Mati rasa di ujung jari tangan atau kaki** ① ② ③ ④
36. **Lainnya (sebutkan spesifik)** ① ② ③ ④
37. **Apakah Anda mengalami kerontokan rambut? Mohon sebutkan % kerusakan sejak memulai kemoterapi: _____%**
(0 = tidak ada kerontokan, 100 = kerontokan total)
38. **Apakah wig (rambut palsu) sedang digunakan?** ya/tidak

D: Mata

39. **Mata sakit** ① ② ③ ④
40. **Mata kering** ① ② ③ ④
41. **Mata “gatal” atau iritasi** ① ② ③ ④
42. **Mata berair** ① ② ③ ④
43. **Infeksi di dalam atau di sekitar mata (konjungtivitis)** ① ② ③ ④

44. Penglihatan kabur atau ganda (0) (1) (2) (3) (4)
 45. Lainnya (sebutkan spesifik) (0) (1) (2) (3) (4)

E: Kesehatan Fisik Umum

46. Sakit kepala (0) (1) (2) (3) (4)
 47. Kelemahan fisik (0) (1) (2) (3) (4)
 48. Kelelahan atau kelemahan (0) (1) (2) (3) (4)
 49. Infeksi (sebutkan spesifik.....) (0) (1) (2) (3) (4)
 50. Sakit atau "nyeri" sendi (0) (1) (2) (3) (4)
 51. Pergelangan kaki bengkak (0) (1) (2) (3) (4)
 52. Sakit punggung (0) (1) (2) (3) (4)
 53. Gejala seperti "flu" (0) (1) (2) (3) (4)
 54. Berkeringat malam hari (0) (1) (2) (3) (4)
 55. Tangan gemetar (0) (1) (2) (3) (4)
 56. Otot kaku atau sakit (0) (1) (2) (3) (4)
 57. Merasa panas setelah kemoterapi (0) (1) (2) (3) (4)
 58. "Sistitis" atau peradangan kandung kemih (0) (1) (2) (3) (4)
 59. Merasa tidak enak badan (0) (1) (2) (3) (4)
 60. Lainnya (sebutkan spesifik) (0) (1) (2) (3) (4)

F: Suasana Hati dan Perasaan

Sejak pengobatan Anda, apakah Anda merasakan gejala-gejala di bawah ini lebih sering daripada biasanya? Mohon tunjukkan tingkat keparahan masalah pada skala 0-4.

61. Kesulitan berkonsentrasi (0) (1) (2) (3) (4)
 62. Perubahan suasana hati (0) (1) (2) (3) (4)
 63. Kecemasan (0) (1) (2) (3) (4)
 64. Merasa rendah diri atau tertekan (0) (1) (2) (3) (4)
 65. Merasa bersedih (0) (1) (2) (3) (4)
 66. Merasa marah (0) (1) (2) (3) (4)
 67. Merasa agresif atau mudah tersinggung (0) (1) (2) (3) (4)
 68. Merasa gelisah (0) (1) (2) (3) (4)
 69. Sulit tidur atau terganggu (0) (1) (2) (3) (4)
 70. Lainnya (sebutkan spesifik) (0) (1) (2) (3) (4)
 71. Apakah kemoterapi, yang menyebabkan Anda merasa cemas? (0) (1) (2) (3) (4)
 72. Sebelum menjalani kemoterapi, apakah Anda mengalami mual? (0) (1) (2) (3) (4)
 73. Sebelum menjalani kemoterapi, apakah Anda mengalami muntah? (0) (1) (2) (3) (4)

G: Pertanyaan Yang Hanya Berlaku Untuk Wanita

Pada minggu-minggu setelah pengobatan kemoterapi, apakah Anda mengalami salah satu dari masalah berikut ini? Mohon sebutkan tingkat keparahan masalah tersebut pada skala 0-4.

74. "Luka" pada vagina (0) (1) (2) (3) (4)
 75. Keputihan (0) (1) (2) (3) (4)
 76. Lainnya (sebutkan spesifik) (0) (1) (2) (3) (4)
 77. Apakah Anda masih mengalami menstruasi? Ya/Tidak

Lampiran 4. Surat Izin dan Etik Penelitian



KEMENTERIAN PENDIDIKAN KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEPERAWATAN
JL. PERINTIS KEMERDEKAAN KM. 10, MAKASSAR 90045
TELEPON (0411) 586200, (6 SALURAN), 584200, FAX (0411) 585188
Laman: www.unhas.ac.id

Nomor : 01613/UN4.18/PT.01.04/2024
Lampiran : -
Hal : Permohonan Izin Penelitian

21 Mei 2024

Yth. Direktur RSUP. dr. Wahidin Sudirohusodo
MAKASSAR

Dengan hormat disampaikan bahwa dalam rangka penyelesaian studi Mahasiswa Program Studi Ilmu Keperawatan, Fakultas Keperawatan Universitas Hasanuddin, maka dengan ini kami mohon agar mahasiswa tersebut namanya di bawah ini :

Nama : Lilian Arifka Juli Abdullah
NIM : R011201060
Program Studi : Ilmu Keperawatan
Judul Penelitian : Hubungan Karakteristik Pemberian Obat Kemoterapi dengan Kejadian Efek Samping pada Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP Dr. Wahidin Sudirohusodo.

Dapat diberikan izin melakukan penelitian di RSUP Dr. Wahidin Sudirohusodo, yang akan dilaksanakan pada bulan Mei s.d Juni 2024. Adapun Metode pengambilan sampel/data dengan : Kuesioner dan Rekam Medis.

Besar harapan kami, agar permohonan izin ini dapat dipertimbangkan untuk diterima.

Demikian permohonan kami, atas perhatiannya disampaikan terima kasih.

a.n. Dekan
Plh Wakil Dekan Bidang Akademik dan
Kemahasiswaan



Dr. Takdir Tahir, S.Kep.,NS.,M.Kes.
NIP. 19770421 200912 1 003

Tembusan:

1. Dekan "sebagai laporan"
2. Kepala Bagian Tata Usaha Fak. Keperawatan Unhas.
3. Arsip





**KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEPERAWATAN
KOMITE ETIK PENELITIAN KESEHATAN**

Sekretariat : Lantai 2 Fakultas Keperawatan UNEAS
Jl. Perintis Kemerdekaan Kampus Tamalaea Km.10 Makassar 90245
Laman : kepi_fkip@unhas.ac.id

REKOMENDASI PERSETUJUAN ETIK

Nomor : 1052/UN4.18.3/TP.01.02/2024

Tanggal: 03 Juni 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH2405094	No Sponsor Protokol	
Peneliti Utama	Lilian Arifka Juli Abdullah	Sponsor	
Judul Penelitian	Hubungan Karakteristik Pemberian Obat Kemoterapi dengan Kejadian Efek Samping pada Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP Dr. Wahidin Sudirohusodo		
No Versi Protokol	1	Tanggal Versi	28 Mei 2024
No Versi PSP	1	Tanggal Versi	28 Mei 2024
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard	Masa berlaku 03 Juni 2024 sampai 03 Juni 2025	Frekuensi review lanjutan
Ketua KEPK	Nama : Dr. Kadek Ayu Erika, S.Kep., Ns., M.Kes	Tanda Tangan	
Sekretaris KEPK	Nama : Dr. Hastuti, S.Kep., Ns., M.Kes	Tanda Tangan	

Kewajiban Peneliti Utama :

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komite Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan *Suspected Unexpected Serious Adverse Reaction* (SUSAR) dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (*protocol deviation/violation*)
- Mematuhi semua peraturan yang ditentukan

Lampiran 5. Daftar Coding

DAFTAR CODING

1. Coding Jenis Kelamin

Jenis Kelamin (JK)	Kode
Laki-laki	1
Perempuan	2

2. Coding Usia

Usia	Kode
Young adult: 20-39 tahun	1
Middle-aged adult: 40-59 th	2
Older adult: 60-79 tahun	3
Elderly : ≥ 80 tahun	4

3. Coding Pekerjaan

Pekerjaan (PK)	Kode
PNS	1
IRT	2
Wiraswasta	3
Pensiunan	4
Lainnya	5

4. Coding Pendidikan Terakhir

Pendidikan Terakhir (PT)	Kode
SD	1
SMP	2
SMA	3
Diploma (DIII)	4
Sarjana (S1)	5

5. Coding Stadium Klinis Kanker

Stadium Klinis Kanker (SKK)	Kode
Stadium IIIA	1
Stadium IIIB	2
Stadium IIIC	3
Stadium IV	4

6. *Coding* Tujuan Kemoterapi

Tujuan Kemoterapi (TK)	Kode
Neoadjuvant (NAC)	1
Adjuvant (AC)	2

7. *Coding* Jenis Obat Kemoterapi

Jenis Obat Kemoterapi (JOK)	Kode
Agen Alkilasi	1
Antimetabolit	2
Agen Antimikrotubular	3
Miscellaneous Antineoplastics	4
Topoisimerase Inhibitors I	5
Topoisimerase Inhibitors II	6

8. *Coding* Kombinasi Regimen Kemoterapi

Kombinasi Regimen Kemo (KRK)	Kode
Regimen 1,3,6	1
Regimen 1,2,6	2
Regimen 1,2,3	3
Regimen 1,6	4
Regimen 3	5

9. *Coding* Variabel Dummy Jenis Obat Kemoterapi

Keterangan	Kode
Tidak Menggunakan	0
Menggunakan	1

10. *Coding* Penyakit Penyerta

Penyakit Penyerta (PP)	Kode
Ya	1
Tidak	2

Lampiran 6. Master Tabel

Master Tabel Karakteristik Responden dan Efek Samping Kemoterapi Sistem Pencernaan (A)

No. Responden	Jenis Kelamin	Usia	Pekerjaan	Pendidikan Terakhir	Berat Badan	Penyakit Penyerta	A1	A2	A3	A4	A5	A6	A7	A8	A9	A10	Total
1	2	3	2	1	4	2	0	1	2	1	1	0	0	0	0	0	5
2	2	2	2	5	3	2	0	1	2	1	1	0	1	0	1	0	7
3	2	2	2	1	3	2	2	2	1	2	2	0	0	0	2	0	11
4	2	2	1	5	3	2	0	1	2	1	1	1	0	0	1	0	7
5	2	2	2	2	3	2	2	2	1	2	2	0	2	2	0	0	13
6	2	2	1	5	2	2	2	2	1	2	2	0	0	2	2	0	13
7	2	2	2	1	2	2	0	1	2	1	1	0	0	0	2	1	8
8	2	2	2	3	2	1	3	3	1	2	3	0	2	1	2	0	17
9	2	2	1	5	3	1	2	2	1	2	2	3	0	0	0	0	12
10	2	2	2	2	3	1	4	2	1	2	3	0	0	0	0	0	12
11	2	2	2	3	4	2	1	2	2	1	1	0	0	0	2	2	11
12	2	2	2	3	2	1	1	2	2	1	1	0	0	0	2	0	9
13	2	1	2	2	3	2	0	1	2	1	1	0	0	0	2	0	7
14	2	2	2	5	4	2	3	3	1	2	3	3	0	0	2	0	17
15	2	2	3	3	3	1	2	2	2	1	1	2	0	0	2	0	12
16	2	1	2	1	4	1	1	2	1	2	2	0	1	0	1	0	10
17	2	2	5	1	3	2	3	3	1	2	3	1	1	0	1	0	15
18	2	3	2	2	4	2	3	3	1	2	2	0	2	0	2	0	15
19	2	2	2	3	4	1	1	2	1	2	2	3	0	0	3	0	14
20	2	1	2	4	2	2	1	2	2	1	1	0	0	0	1	0	8

21	2	1	1	5	2	1	4	2	1	3	3	3	0	0	0	0	16
22	2	3	4	5	4	1	0	1	2	1	1	0	0	0	0	0	5
23	2	2	2	5	2	2	0	1	2	1	1	0	0	1	2	0	8
24	2	3	4	5	1	1	3	3	1	2	3	0	0	0	2	0	14
25	2	3	3	1	4	2	0	1	2	1	1	1	0	0	0	0	6
26	2	2	2	1	2	2	1	3	1	2	2	0	1	0	0	0	10
27	2	1	1	5	1	2	1	2	1	2	3	0	1	0	0	0	10
28	2	2	2	1	2	2	2	2	1	2	2	0	0	0	2	0	11
29	2	2	2	1	1	2	2	2	1	3	3	2	0	0	2	0	15
30	2	2	2	1	2	2	3	2	1	2	2	2	2	0	3	0	17
31	2	1	2	1	2	2	1	2	1	2	2	3	0	0	1	0	12
32	2	1	2	2	2	2	1	2	2	1	1	0	1	0	1	0	9
33	2	3	4	5	2	2	3	2	2	1	1	3	0	0	1	0	13
34	2	2	2	2	2	2	3	2	1	2	2	3	1	0	1	0	15
35	2	2	2	1	3	1	4	2	1	2	3	3	0	0	2	0	17
36	2	2	2	1	3	2	1	2	2	1	1	1	0	0	1	0	9
37	2	2	1	5	4	2	1	2	1	2	2	3	0	0	1	0	12
38	2	2	1	5	3	1	2	2	1	2	2	3	0	0	0	0	12
39	2	2	2	2	3	1	4	2	1	2	3	0	0	0	0	0	12
40	2	2	2	3	4	2	1	2	2	1	1	0	0	0	2	2	11
41	2	3	4	5	1	1	3	2	2	1	1	3	0	0	1	0	13
42	2	2	2	2	1	1	3	2	1	2	2	3	1	0	1	0	15
43	2	2	2	5	4	2	3	3	1	2	3	3	0	0	2	0	17
44	2	2	2	1	2	2	2	2	1	2	2	0	0	0	2	0	11
45	2	1	2	1	4	1	1	2	1	2	2	0	1	0	1	0	10

46	2	3	2	1	4	1	0	1	2	1	1	0	0	0	0	0	5
47	2	2	2	5	3	2	0	1	2	1	1	0	1	0	1	0	7
48	2	2	2	1	3	2	2	2	1	2	2	0	0	0	2	0	11
49	2	2	2	3	4	1	1	2	1	2	2	3	0	0	3	0	14
50	2	1	2	4	2	2	1	2	2	1	1	0	0	0	1	0	8
51	2	1	1	5	2	1	4	2	1	3	3	3	0	0	0	0	16
52	2	3	4	5	4	1	0	1	2	1	1	0	0	0	0	0	5
53	2	2	2	5	2	2	0	1	2	1	1	0	0	1	2	0	8
54	2	3	4	5	1	1	3	3	1	2	3	0	0	0	2	0	14
55	2	3	3	1	4	2	0	1	2	1	1	1	0	0	0	0	6
56	2	2	2	1	2	2	1	3	1	2	2	0	1	0	0	0	10
57	2	2	5	1	3	2	3	3	1	2	3	1	1	0	1	0	15
58	2	3	2	2	4	2	3	3	1	2	2	0	2	0	2	0	15
59	2	2	2	3	4	2	1	2	1	2	2	3	0	0	3	0	14
60	2	1	2	4	2	2	1	2	2	1	1	0	0	0	1	0	8
61	2	1	1	5	2	2	4	2	1	3	3	3	0	0	0	0	16
62	2	2	2	1	2	2	1	3	1	2	2	0	1	0	0	0	10
63	2	1	1	5	1	2	1	2	1	2	3	0	1	0	0	0	10
64	2	2	2	1	2	2	2	2	1	2	2	0	0	0	2	0	11
65	2	2	2	1	1	2	2	2	1	3	3	2	0	0	2	0	15

Master Tabel Efek Samping Kemoterapi Mulut & Hidung (B) dan Rambut & Kulit (C)

B1	B2	B3	B4	B5	B6	B7	B8	B9	B10	B11	B12	Total	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	Total
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2	3
0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	2
0	2	0	0	1	1	2	2	0	2	0	0	8	1	2	2	1	2	2	2	2	0	2	16
0	0	0	0	0	0	0	1	1	0	0	0	2	0	2	1	0	0	0	0	0	0	2	5
0	0	0	0	1	1	0	2	0	0	0	0	4	0	0	0	0	0	0	0	2	0	2	4
1	0	0	0	0	0	1	3	0	0	0	0	4	0	2	0	0	0	0	2	0	0	2	6
0	0	0	0	0	0	0	2	0	0	0	0	2	0	0	1	0	1	0	0	0	0	2	4
0	2	0	0	1	1	0	4	0	0	2	2	10	0	3	0	0	0	0	0	0	0	2	5
0	0	0	0	0	1	0	3	0	3	0	0	7	0	1	0	0	0	0	0	0	0	2	3
2	0	0	2	3	3	3	3	1	0	0	0	15	1	1	1	0	0	0	2	0	0	2	7
0	0	0	0	2	0	0	4	0	4	0	0	10	0	1	0	0	0	0	2	0	0	2	5
0	0	0	0	1	1	2	3	0	3	0	0	10	0	0	2	2	3	3	2	2	0	2	16
0	2	0	0	0	0	4	2	0	0	0	0	6	2	0	2	0	0	0	0	0	0	2	6
0	1	0	0	1	1	0	0	3	0	0	0	5	0	1	0	0	0	0	0	0	0	2	3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	2	0	0	2	7
1	0	1	1	1	1	2	2	0	0	0	0	8	1	0	1	0	1	1	1	0	0	2	7
0	0	0	0	0	0	0	0	0	3	0	0	3	0	0	1	2	0	0	2	2	0	2	9
2	0	2	1	2	2	2	3	0	3	0	0	15	0	0	2	0	1	1	2	2	0	2	10
3	0	0	3	3	3	3	2	0	0	0	0	14	0	2	2	0	0	0	0	2	0	2	8
0	0	1	0	2	2	0	1	0	0	0	0	6	0	1	1	0	1	1	0	0	0	2	6
0	0	0	4	1	1	4	2	0	3	0	0	15	0	1	2	0	1	0	0	0	0	2	6
0	0	0	0	0	0	0	3	0	0	0	0	3	0	2	0	0	0	0	0	0	0	2	4

0	0	0	0	2	2	2	1	0	0	0	0	7	0	1	1	2	2	2	2	0	0	2	12
0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	2
0	0	0	0	0	0	0	3	0	2	0	0	5	0	0	2	0	0	0	2	1	0	2	7
0	1	0	0	1	1	0	3	0	3	0	0	8	0	0	1	0	1	0	1	0	0	2	5
0	0	0	0	0	0	0	4	0	0	0	0	4	0	0	1	0	1	1	0	0	0	2	5
0	0	1	1	2	2	2	3	0	4	0	0	15	0	2	2	0	2	2	2	2	0	2	14
3	3	2	4	3	3	4	3	0	4	0	0	23	0	1	2	1	0	0	2	2	0	2	10
0	0	1	0	2	2	0	3	0	0	0	0	8	0	1	0	0	0	0	2	0	0	2	5
0	0	0	0	0	1	0	1	0	0	0	0	2	0	0	1	0	1	0	1	0	0	2	5
0	0	0	0	0	1	1	0	0	0	0	0	2	0	1	1	0	1	0	3	0	0	2	8
0	0	0	0	0	0	0	3	0	0	0	0	3	0	1	2	0	2	0	2	0	0	2	9
0	0	1	1	2	2	1	3	0	3	0	0	13	0	1	0	0	0	0	0	2	0	2	5
0	0	0	0	0	0	0	2	0	0	0	0	2	0	0	2	0	0	0	2	2	0	2	8
0	0	0	0	3	3	0	4	0	0	0	0	10	0	0	2	1	2	2	0	3	0	2	12
0	0	0	0	0	1	0	1	0	0	0	0	2	0	0	1	0	1	0	1	0	0	2	5
0	0	0	0	0	1	0	3	0	3	0	0	7	0	1	0	0	0	0	0	0	0	2	3
2	0	0	2	3	3	3	3	1	0	0	0	15	1	1	1	0	0	0	2	0	0	2	7
0	0	0	0	2	0	0	4	0	4	0	0	10	0	1	0	0	0	0	2	0	0	2	5
0	0	0	0	0	0	0	3	0	0	0	0	3	0	1	2	0	2	0	2	0	0	2	9
0	0	1	1	2	2	1	3	0	3	0	0	13	0	1	0	0	0	0	0	2	0	2	5
0	1	0	0	1	1	0	0	3	0	0	0	5	0	1	0	0	0	0	0	0	0	2	3
0	0	1	1	2	2	2	3	0	4	0	0	15	0	2	2	0	2	2	2	2	0	2	14
1	0	1	1	1	1	2	2	0	0	0	0	8	1	0	1	0	1	1	1	0	0	2	7
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2	3
0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	2

0	2	0	0	1	1	2	2	0	2	0	0	8	1	2	2	1	2	2	2	2	0	2	16
3	0	0	3	3	3	3	2	0	0	0	0	14	0	2	2	0	0	0	0	2	0	2	8
0	0	1	0	2	2	0	1	0	0	0	0	6	0	1	1	0	1	1	0	0	0	2	6
0	0	0	4	1	1	4	2	0	3	0	0	15	0	1	2	0	1	0	0	0	0	2	6
0	0	0	0	0	0	0	3	0	0	0	0	3	0	2	0	0	0	0	0	0	0	2	4
0	0	0	0	2	2	2	1	0	0	0	0	7	0	1	1	2	2	2	2	0	0	2	12
0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	2
0	0	0	0	0	0	0	3	0	2	0	0	5	0	0	2	0	0	0	2	1	0	2	7
0	1	0	0	1	1	0	3	0	3	0	0	8	0	0	1	0	1	0	1	0	0	2	5
0	0	0	0	0	0	0	0	0	3	0	0	3	0	0	1	2	0	0	2	2	0	2	9
2	0	2	1	2	2	2	3	0	3	0	0	15	0	0	2	0	1	1	2	2	0	2	10
3	0	0	3	3	3	3	2	0	0	0	0	14	0	2	2	0	0	0	0	2	0	2	8
0	0	1	0	2	2	0	1	0	0	0	0	6	0	1	1	0	1	1	0	0	0	2	6
0	0	0	4	1	1	4	2	0	3	0	0	15	0	1	2	0	1	0	0	0	0	2	6
0	1	0	0	1	1	0	3	0	3	0	0	8	0	0	1	0	1	0	1	0	0	2	5
0	0	0	0	0	0	0	4	0	0	0	0	4	0	0	1	0	1	1	0	0	0	2	5
0	0	1	1	2	2	2	3	0	4	0	0	15	0	2	2	0	2	2	2	2	0	2	14
3	3	2	4	3	3	4	3	0	4	0	0	23	0	1	2	1	0	0	2	2	0	2	10

Master Tabel Efek Samping Kemoterapi Mata (D) dan Kesehatan Fisik Umum (E)

D1	D2	D3	D4	D5	D6	D7	Total	E1	E2	E3	E4	E5	E6	E7	E8	E9	E10	E11	E12	E13	E14	E15	Total
0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	3	1	0	2	0	0	1	0	10
0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	1	0	1	0	0	0	6
0	0	2	2	0	0	0	4	3	1	1	0	3	0	3	3	2	0	1	4	2	2	0	25
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	0	0	0	0	0	0	2	0	6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	2
0	0	0	0	0	0	0	0	2	2	2	0	2	0	0	0	2	0	0	1	0	2	0	13
0	0	0	0	0	0	0	0	0	4	4	0	0	0	1	1	0	2	0	0	0	2	0	14
0	0	0	0	0	0	0	0	0	3	3	0	0	0	0	0	2	0	0	1	0	2	0	11
1	1	0	2	2	2	0	8	2	3	3	0	3	0	2	0	2	2	1	2	0	3	0	23
0	0	0	0	0	0	0	0	2	2	2	1	2	0	1	0	0	0	0	0	0	2	0	12
0	0	0	3	0	2	0	5	2	2	2	0	2	0	2	2	2	2	0	2	0	2	0	20
0	0	0	0	3	2	0	5	0	2	2	0	0	0	0	0	0	0	0	0	0	2	0	6
0	0	0	0	0	0	0	0	1	3	3	0	3	0	2	0	0	2	0	0	0	3	0	17
0	0	0	0	0	0	0	0	1	0	2	0	2	0	1	2	2	0	1	2	0	2	0	15
1	1	0	1	0	1	0	4	1	1	1	1	0	1	1	1	1	1	1	2	2	2	0	16
0	0	0	0	0	0	0	0	2	3	3	0	1	0	0	0	1	1	2	2	0	0	0	15
0	0	0	1	0	2	0	3	0	2	2	0	0	0	0	1	1	0	0	1	0	2	0	9
0	0	0	3	2	0	0	5	2	2	2	0	0	2	2	2	2	0	1	2	1	4	0	22
0	0	1	0	0	0	0	1	2	2	2	0	1	0	0	0	0	0	1	1	0	2	0	11
0	2	0	0	0	0	0	2	3	4	4	0	0	0	2	1	3	0	1	0	0	4	0	22
0	0	0	0	0	0	0	0	1	1	1	0	0	1	1	0	0	0	0	2	0	1	0	8

1	0	0	0	0	0	0	1	2	2	2	0	2	0	2	1	2	0	0	2	2	2	0	19
0	0	0	0	0	0	0	0	1	2	2	0	0	0	0	0	0	0	0	0	0	2	0	7
0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	1	0	4
0	0	0	0	0	1	0	1	0	1	1	0	1	0	2	2	0	0	0	0	0	2	0	9
0	0	0	0	0	0	0	0	2	0	0	0	1	0	1	0	1	0	0	0	0	1	0	6
0	0	0	0	0	2	2	4	2	2	2	0	3	0	1	0	0	0	2	3	0	3	0	18
2	0	2	0	2	1	0	7	3	3	3	0	2	0	2	2	1	0	1	3	0	4	0	24
0	0	0	1	0	1	0	2	1	0	0	0	3	0	1	0	0	0	2	1	0	1	0	9
0	0	0	0	0	0	0	0	1	2	2	0	1	0	0	1	0	0	0	1	0	2	0	10
0	0	0	0	0	1	0	1	2	2	2	0	0	0	2	2	2	0	0	1	0	2	0	15
0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	0	0	0	0	1	0	2	0	7
0	0	0	0	0	0	0	0	1	3	3	0	3	0	1	0	0	0	0	0	0	2	0	13
0	0	0	0	0	0	0	0	2	2	2	0	2	2	2	2	2	2	1	2	0	3	0	24
0	0	0	1	0	0	0	1	0	3	3	20	2	0	2	1	1	2	0	2	1	0	0	37
0	0	0	0	0	0	0	0	1	2	2	0	1	0	0	1	0	0	0	1	0	2	0	10
0	0	0	0	0	0	0	0	0	3	3	0	0	0	0	0	2	0	0	1	0	2	0	11
1	1	0	2	2	2	0	8	2	3	3	0	3	0	2	0	2	2	1	2	0	3	0	23
0	0	0	0	0	0	0	0	2	2	2	1	2	0	1	0	0	0	0	0	0	2	0	12
0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	0	0	0	0	1	0	2	0	7
0	0	0	0	0	0	0	0	1	3	3	0	3	0	1	0	0	0	0	0	0	2	0	13
0	0	0	0	0	0	0	0	1	3	3	0	3	0	2	0	0	2	0	0	0	3	0	17
0	0	0	0	0	2	2	4	2	2	2	0	3	0	1	0	0	0	2	3	0	3	0	18
1	1	0	1	0	1	0	4	1	1	1	1	0	1	1	1	1	1	2	2	2	0	0	16
0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	3	1	0	2	0	0	1	0	10
0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	1	0	1	0	0	0	6

0	0	2	2	0	0	0	4	3	1	1	0	3	0	3	3	2	0	1	4	2	2	0	25
0	0	0	3	2	0	0	5	2	2	2	0	0	2	2	2	2	0	1	2	1	4	0	22
0	0	1	0	0	0	0	1	2	2	2	0	1	0	0	0	0	0	1	1	0	2	0	11
0	2	0	0	0	0	0	2	3	4	4	0	0	0	2	1	3	0	1	0	0	4	0	22
0	0	0	0	0	0	0	0	1	1	1	0	0	1	1	0	0	0	0	2	0	1	0	8
1	0	0	0	0	0	0	1	2	2	2	0	2	0	2	1	2	0	0	2	2	2	0	19
0	0	0	0	0	0	0	0	1	2	2	0	0	0	0	0	0	0	0	0	0	2	0	7
0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	1	0	4
0	0	0	0	0	1	0	1	0	1	1	0	1	0	2	2	0	0	0	0	0	2	0	9
0	0	0	0	0	0	0	0	2	3	3	0	1	0	0	0	1	1	2	2	0	0	0	15
0	0	0	1	0	2	0	3	0	2	2	0	0	0	0	1	1	0	0	1	0	2	0	9
0	0	0	3	2	0	0	5	2	2	2	0	0	2	2	2	2	0	1	2	1	4	0	22
0	0	1	0	0	0	0	1	2	2	2	0	1	0	0	0	0	0	1	1	0	2	0	11
0	2	0	0	0	0	0	2	3	4	4	0	0	0	2	1	3	0	1	0	0	4	0	22
0	0	0	0	0	1	0	1	0	1	1	0	1	0	2	2	0	0	0	0	0	2	0	9
0	0	0	0	0	0	0	0	2	0	0	0	1	0	1	0	1	0	0	0	0	1	0	6
0	0	0	0	0	2	2	4	2	2	2	0	3	0	1	0	0	0	2	3	0	3	0	18
2	0	2	0	2	1	0	7	3	3	3	0	2	0	2	2	1	0	1	3	0	4	0	24

Master Tabel Efek Samping Kemoterapi Suasana Hati & Perasaan (F) dan Sistem Reproduksi (G)

F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12	F13	Total	G1	G2	G3	G4	Total	Total Akumulatif
0	1	1	1	1	0	0	0	0	0	1	0	0	5	0	0	0	2	2	25
0	2	2	2	2	2	2	0	0	0	2	0	0	14	0	0	0	2	2	32
2	2	2	2	2	2	2	2	3	0	3	1	1	24	0	0	0	2	2	90
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	17
1	1	0	0	0	0	0	0	0	0	0	1	1	4	0	0	0	2	2	33
0	0	2	2	2	0	0	1	0	0	2	1	1	11	0	0	0	2	2	38
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	28
2	3	2	4	4	4	2	0	2	0	2	2	2	29	0	0	0	2	2	77
1	0	0	0	0	0	0	0	0	0	0	1	1	3	0	0	0	2	2	38
3	1	1	0	0	0	0	3	3	0	1	0	0	12	0	0	0	2	2	79
0	0	0	0	0	0	0	2	2	0	0	0	0	4	3	0	0	2	5	47
0	2	2	2	2	2	2	0	0	0	2	0	0	14	0	0	0	2	2	76
0	0	0	0	0	0	0	0	3	0	0	0	0	3	0	0	0	2	2	35
1	0	0	0	0	0	0	3	3	0	0	1	1	9	0	0	0	1	1	52
0	2	2	2	2	1	2	2	2	0	2	0	0	17	0	0	0	2	2	53
1	2	2	2	2	2	2	2	2	0	2	0	0	19	0	0	0	1	1	65
0	3	2	2	2	3	3	3	4	0	2	1	0	25	0	0	0	2	2	69
2	1	2	0	0	0	0	0	0	0	2	0	0	7	0	0	0	2	2	61
1	1	1	1	1	1	1	1	1	0	0	0	0	9	0	0	0	2	2	74
0	2	1	1	2	1	1	1	2	0	1	0	0	12	0	0	0	2	2	46
3	3	3	2	3	3	3	3	0	0	2	0	0	25	1	0	1	2	4	90
0	1	0	1	1	1	1	1	2	0	1	0	0	9	0	0	0	2	2	31

0	2	2	2	2	2	2	2	2	0	1	0	0	17	0	0	1	2	3	67
0	0	1	0	0	0	0	0	2	1	0	0	0	4	0	0	0	2	2	30
0	1	1	1	1	1	1	1	0	0	1	0	0	8	0	0	0	2	2	32
0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	1	2	3	38
0	1	1	1	1	1	1	0	0	0	1	0	0	7	0	0	0	1	1	33
0	3	3	3	3	3	3	3	3	0	2	0	0	26	0	0	0	2	2	90
2	2	2	2	2	2	2	2	2	0	2	0	0	20	0	0	0	2	2	101
1	2	2	2	2	2	2	2	2	0	2	1	1	21	0	0	0	2	2	64
0	1	0	1	1	1	1	0	0	0	1	0	0	6	0	3	0	1	4	39
0	2	0	2	2	2	2	2	2	0	0	0	0	14	0	0	0	2	2	51
0	1	1	0	0	0	0	0	0	0	1	0	0	3	0	0	0	2	2	37
0	2	1	2	2	2	2	2	1	0	1	0	0	15	0	0	0	2	2	63
0	2	2	2	2	2	2	2	2	0	2	0	0	18	0	0	0	2	2	71
0	0	0	0	0	0	0	2	2	0	0	0	0	4	0	0	0	2	2	75
0	1	0	1	1	1	1	0	0	0	1	0	0	6	0	3	0	1	4	39
1	0	0	0	0	0	0	0	0	0	0	1	1	3	0	0	0	2	2	38
3	1	1	0	0	0	0	3	3	0	1	0	0	12	0	0	0	2	2	79
0	0	0	0	0	0	0	2	2	0	0	0	0	4	3	0	0	2	5	47
0	1	1	0	0	0	0	0	0	0	1	0	0	3	0	0	0	2	2	37
0	2	1	2	2	2	2	2	1	0	1	0	0	15	0	0	0	2	2	63
1	0	0	0	0	0	0	3	3	0	0	1	1	9	0	0	0	1	1	52
0	3	3	3	3	3	3	3	3	0	2	0	0	26	0	0	0	2	2	90
1	2	2	2	2	2	2	2	2	0	2	0	0	19	0	0	0	1	1	65
0	1	1	1	1	0	0	0	0	0	1	0	0	5	0	0	0	2	2	25
0	2	2	2	2	2	2	0	0	0	2	0	0	14	0	0	0	2	2	32

2	2	2	2	2	2	2	2	3	0	3	1	1	24	0	0	0	2	2	90
1	1	1	1	1	1	1	1	1	0	0	0	0	9	0	0	0	2	2	74
0	2	1	1	2	1	1	1	2	0	1	0	0	12	0	0	0	2	2	46
3	3	3	2	3	3	3	3	0	0	2	0	0	25	1	0	1	2	4	90
0	1	0	1	1	1	1	1	2	0	1	0	0	9	0	0	0	2	2	31
0	2	2	2	2	2	2	2	2	0	1	0	0	17	0	0	1	2	3	67
0	0	1	0	0	0	0	0	2	1	0	0	0	4	0	0	0	2	2	30
0	1	1	1	1	1	1	1	0	0	1	0	0	8	0	0	0	2	2	32
0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	1	2	3	38
0	3	2	2	2	3	3	3	4	0	2	1	0	25	0	0	0	2	2	69
2	1	2	0	0	0	0	0	0	0	2	0	0	7	0	0	0	2	2	61
1	1	1	1	1	1	1	1	1	0	0	0	0	9	0	0	0	2	2	74
0	2	1	1	2	1	1	1	2	0	1	0	0	12	0	0	0	2	2	46
3	3	3	2	3	3	3	3	0	0	2	0	0	25	1	0	1	2	4	90
0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	2	2	37
0	1	1	1	1	1	1	0	0	0	1	0	0	7	0	0	0	1	1	33
0	3	3	3	3	3	3	3	3	0	2	0	0	26	0	0	0	2	2	90
2	2	2	2	2	2	2	2	2	0	2	0	0	20	0	0	0	2	2	101

Lampiran 7. Hasil Analisa Data

Statistics

		Usia	Berat Badan
N	Valid	65	65
	Missing	0	0
Mean		48.78	52.31
Median		49.00	51.00
Std. Deviation		10.210	10.919
Minimum		32	35
Maximum		69	73

Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	20-39 Tahun	13	20.0	20.0	20.0
	40-59 Tahun	40	61.5	61.5	81.5
	60-79 Tahun	12	18.5	18.5	100.0
	Total	65	100.0	100.0	

Berat Badan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	30-40 kg	8	12.3	12.3	12.3
	41-50 kg	23	35.4	35.4	47.7
	51-60 kg	16	24.6	24.6	72.3
	>60 kg	18	27.7	27.7	100.0
	Total	65	100.0	100.0	

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Perempuan	65	100.0	100.0	100.0

Pendidikan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	SD sederajat	23	35.4	35.4	35.4
	SMP sederajat	9	13.8	13.8	49.2
	SMA sederajat	8	12.3	12.3	61.5
	DI/DII/DIII	3	4.6	4.6	66.2
	S1/S2/S3	22	33.8	33.8	100.0
	Total	65	100.0	100.0	

Pekerjaan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	PNS	10	15.4	15.4	15.4
	IRT	44	67.7	67.7	83.1
	Wiraswasta	3	4.6	4.6	87.7
	Pensiunan	6	9.2	9.2	96.9
	Lainnya	2	3.1	3.1	100.0
	Total	65	100.0	100.0	

Penyakit Penyerta

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	21	32.3	32.3	32.3
	Tidak	44	67.7	67.7	100.0
	Total	65	100.0	100.0	

Jenis Obat Kemoterapi * Efek Samping Crosstabulation

		Efek Samping			Total
		Ringan	Sedang	Berat	
Jenis Obat Kemoterapi	Regimen 1,3,6	Count	1	10	22
		Expected Count	.5	12.7	33.0
	Regimen 1,2,6	Count	0	6	6
		Expected Count	.2	4.6	12.0
	Regimen 1,2,3	Count	0	2	5
		Expected Count	.1	2.7	7.0

	Regimen 1,6	Count	0	6	0	6
		Expected Count	.1	2.3	3.6	6.0
	Regimen 3	Count	0	1	6	7
		Expected Count	.1	2.7	4.2	7.0
Total		Count	1	25	39	65
		Expected Count	1.0	25.0	39.0	65.0

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	50.186 ^a	18	.000
Likelihood Ratio	29.863	18	.039
N of Valid Cases	65		

a. 27 cells (90.0%) have expected count less than 5. The minimum expected count is .02.

Model Summary

Model	R	R Square	Adjusted R Square	Std. Error of the Estimate
1	.868 ^a	.753	.737	.270

a. Predictors: (Constant), TI2x, Antimetabolit, Agen Mikrotubular, AAX

ANOVA^a

Model		Sum of Squares	df	Mean Square	F	Sig.
1	Regression	13.400	4	3.350	45.839	.000 ^b
	Residual	4.385	60	.073		
	Total	17.785	64			

a. Dependent Variable: Efek Samping

b. Predictors: (Constant), TI2x, Antimetabolit, Agen Mikrotubular, AAX

Coefficients^a

Model		Unstandardized Coefficients		Standardized Coefficients	t	Sig.
		B	Std. Error	Beta		
1	(Constant)	2.725	.148		18.400	.000
	Antimetabolit	.700	.133	.599	5.275	.000
	Inhibitor Mitosis	.686	.119	.587	5.751	.000
	Agen Alkilasi	-1.411	.170	-1.145	-8.311	.000
	Inhibitor Topoisomerase II	.552	.177	.481	3.115	.003

a. Dependent Variable: Efek Sampling

Crosstab

			Efek Sampling			Total
			Ringan	Sedang	Berat	
Antimetabolit	Tidak	Count	1	18	28	47
		Expected Count	.7	18.1	28.2	47.0
	Ya	Count	0	7	11	18
		Expected Count	.3	6.9	10.8	18.0
Total	Count		1	25	39	65
	Expected Count		1.0	25.0	39.0	65.0

Crosstab

			Efek Sampling			Total
			Ringan	Sedang	Berat	
Inhibitor Mitosis	Tidak	Count	0	12	6	18
		Expected Count	.3	6.9	10.8	18.0
	Ya	Count	1	13	33	47
		Expected Count	.7	18.1	28.2	47.0
Total	Count		1	25	39	65
	Expected Count		1.0	25.0	39.0	65.0

Crosstab

			Efek Sampling			Total
			Ringan	Sedang	Berat	
Inhibitor Topoisomerase II	Tidak	Count	0	12	6	18
		Expected Count	.3	6.9	10.8	18.0
	Ya	Count	1	13	33	47

		Expected Count	.7	18.1	28.2	47.0
Total		Count	1	25	39	65
		Expected Count	1.0	25.0	39.0	65.0

Crosstab

			Efek Samping			Total
			Ringan	Sedang	Berat	
Agen Alkilasi	Tidak	Count	0	12	6	18
		Expected Count	.3	6.9	10.8	18.0
	Ya	Count	1	13	33	47
		Expected Count	.7	18.1	28.2	47.0
Total	Count		1	25	39	65
	Expected Count		1.0	25.0	39.0	65.0

Correlations

			Siklus Kemoterapi	Efek Samping
Spearman's rho	Siklus Kemoterapi	Correlation Coefficient	1.000	-.649**
		Sig. (2-tailed)	.	.046
		N	65	65
	Efek Samping	Correlation Coefficient	.249*	1.000
		Sig. (2-tailed)	.046	.
		N	65	65

** . Correlation is significant at the 0.01 level (2-tailed).

Siklus Kemoterapi * Efek Samping Crosstabulation

			Efek Samping			Total
			Ringan	Sedang	Berat	
Siklus Kemoterapi	Siklus 2	Count	0	9	6	15
		Expected Count	.2	5.8	9.0	15.0
	Siklus3	Count	0	4	8	12
		Expected Count	.2	4.6	7.2	12.0
	Siklus 4	Count	0	6	7	13
		Expected Count	.2	5.0	7.8	13.0
	Siklus 5	Count	1	3	7	11
		Expected Count	.2	4.2	6.6	11.0

	Siklus 6	Count	0	3	7	10
		Expected Count	.2	3.8	6.0	10.0
	Siklus 8	Count	0	0	4	4
		Expected Count	.1	1.5	2.4	4.0
Total		Count	1	25	39	65
		Expected Count	1.0	25.0	39.0	65.0

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	1.213 ^a	2	.545
Likelihood Ratio	1.593	2	.451
Linear-by-Linear Association	.065	1	.799
N of Valid Cases	65		

a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is .46.

Tujuan Kemoterapi * Efek Samping Crosstabulation

			Efek Samping			
			Ringan	Sedang	Berat	Total
Tujuan Kemoterapi	Neoadjuvant	Count	1	11	18	30
		Expected Count	.5	11.5	18.0	30.0
	Adjuvant	Count	0	14	21	35
		Expected Count	.5	13.5	21.0	35.0
Total	Count		1	25	39	65
	Expected Count		1.0	25.0	39.0	65.0

Correlations

		Efek Samping		Stadium Klinis
				Kanker
Spearman's rho	Efek Samping	Correlation Coefficient	1.000	.480**
		Sig. (2-tailed)	.	.002
		N	65	65
	Stadium Klinis Kanker	Correlation Coefficient	-.380**	1.000
		Sig. (2-tailed)	.002	.

N	65	65
---	----	----

** . Correlation is significant at the 0.01 level (2-tailed).

Stadium Klinis Kanker * Efek Samping Crosstabulation

			Efek Samping			
			Ringan	Sedang	Berat	Total
Stadium Klinis Kanker	6	Count	0	4	4	8
		Expected Count	.2	3.0	4.8	8.0
	7	Count	0	7	18	15
		Expected Count	.4	9.6	15.0	25.0
	8	Count	1	13	15	29
		Expected Count	.4	11.2	17.4	29.0
	9	Count	0	1	2	3
		Expected Count	.0	1.2	1.8	3.0
Total	Count	1	25	39	65	
	Expected Count	1.0	25.0	39.0	65.0	